Rebecca Gottschalk - Concepedia

Author

Rebecca Gottschalk

Aptevo Therapeutics (United states)

Also Known As

Rebecca Gottschalk, Rebecca J Gottschalk, Rebecca J. Gottschalk

Publications

507

Citations

H-Index

Concepts

All Affiliations

Aptevo Therapeutics (United states)EKOS Corporation

About

Rebecca Gottschalk is an author at Aptevo Therapeutics (United states) specializing in immunology, cell biology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	176
2	Cell Biology	4	4	176
3	Immunology	4	4	176
4	Natural Sciences	1	1	101
5	Biochemistry	1	1	101

Rebecca Gottschalk

Publications

495

Citations

H-Index

Page 1

	Year	Citations
The RD114/simian type D retrovirus receptor is a neutral amino acid transporter John E.J. Rasko, Jean‐Luc Battini, Rebecca Gottschalk, Proceedings of the National Academy of Sciences	1999	218
A polyphosphate kinase 1 ( <i>ppk1</i> ) mutant of <i>Pseudomonas aeruginosa</i> exhibits multiple ultrastructural and functional defects Cresson D. Fraley, Muhammad H. Rashid, Sam S.-K. Lee, Proceedings of the National Academy of Sciences BiochemistryNatural SciencesVirulence FactorBacteriologyMolecular Biology	2007	101
CD18 Activation Epitopes Induced by Leukocyte Activation Chan Beals, Ana C. Edwards, Rebecca Gottschalk, The Journal of Immunology Leukocyte ActivationAutoimmune DiseaseCell AdhesionImmunologyImmune Regulation	2001	76
MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer Gabriela Hernández‐Hoyos, Toddy Sewell, Robert Bader, Molecular Cancer Therapeutics UrologyCancer ImmunosurveillanceGenitourinary CancerBispecific AntibodyMedicine	2016	70
Abstract 1786: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release Michael R. Comeau, Robert E. Miller, Robert Bader, Cancer Research ImmunologyImmune RegulationCell DeathImmunoeditingImmunologic Mechanism	2018	20
Abstract LB-199: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity with limited cytokine release, is well tolerated in repeat dose toxicology studies in cynomolgus macaques Michael R. Comeau, Rebecca Gottschalk, Mollie Daugherty, Cancer Research Immune RegulationImmunologyImmunoeditingImmunologic MechanismCynomolgus Macaques	2019	10

Page 1